Prednisolone
T-Cell Acute Lymphoblastic Leukemia
Explore 76 assets in T-Cell Acute Lymphoblastic Leukemia →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07072585CT.gov Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) | — | Not Yet Recruiting | — | — | — |
NCT05320380CT.gov A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | — | Withdrawn | — | — | — |
NCT03007147CT.gov Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Cell Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prednisolone (this asset) | Children's Oncology Group | P3 | B · 62 |
| Vincristine Sulfate | Children's Oncology Group | P3 | BB |
| Daunomycin | SWOG Cancer Research Network | P3 | BB |
| Crisantaspase | University of Washington | P3 | BB |
| Pegaspargase | Children's Oncology Group | P3 | BB |
| Mercaptopurine Anhydrous | SWOG Cancer Research Network | P3 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
| Adriamycin | SWOG Cancer Research Network | P3 | BB |
| Cytarabine | SWOG Cancer Research Network | P3 | BB |
+42 more in the T-Cell Acute Lymphoblastic Leukemia cohort
Other indications for Prednisolone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Infantile Spasms | — | P4 | BBB · 79 |
| Non-Hodgkin Lymphoma | — | P3 | BBB · 74 |
| Lymphoma | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prednisolone in T-Cell Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prednisolone-t-cell-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →